Latest news with #AcurxPharmaceuticals
Yahoo
24-07-2025
- Business
- Yahoo
Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., July 24, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2025 financial results on Tuesday, August 12, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, August 12, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference ID: 13755161 International: Click here for participant international Toll-Free access numbers About Ibezapolstat Ibezapolstat is the Company's lead antibiotic candidate preparing for international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®™) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. Acurx previously announced that it had received positive regulatory guidance from the EMA during its Scientific Advice Procedure which confirmed that the clinical, non-clinical and CMC (Chemistry Manufacturing and Controls) information package submitted to EMA supports advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details on Acurx's two planned international Phase 3 clinical trials, 1:1 randomized (designed as non-inferiority vs vancomycin), primary and secondary endpoints, sample size, statistical analysis plan and the overall registration safety database. With mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration program In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year subject to obtaining appropriate financing. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel. To learn more about Acurx Pharmaceuticals and its product pipeline, please visit Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law. Investor Contact:Acurx Pharmaceuticals, P. Luci, President & CEOTel: 917-533-1469Email: davidluci@ View original content: SOURCE Acurx Pharmaceuticals, Inc.
Associated Press
27-06-2025
- Business
- Associated Press
New to The Street Announces the Broadcast of Show Number 675 This Saturday at 6:30 PM EST on Bloomberg Television Featuring: FLOKI, BioVie (NASDAQ: BIVI), Arrive AI ($ARAI), Health In Tech (NASDAQ HIT), and Commercialville T.V.
Show Number 675 is sponsored programming by Ainos (NASDAQ: AIMD), Arrive AI ($ARAI), Acurx Pharmaceuticals (NASDAQ: ACXP), Sustainable Green Team (OTC: SGTM) and Commercialville T.V. commercials NEW YORK CITY, NEW YORK / ACCESS Newswire / June 27, 2025 / New to The Street proudly announces the broadcast of Show Number 675, airing this Saturday at 6:30 PM EST on Bloomberg Television. Show Number 675 marks a major milestone for the nationally syndicated program known for its in-depth interviews and business features spanning emerging technologies, biotech, fintech, and media. Show Number 675 will feature the following companies: Show Number 675 is sponsored programming brought to audiences by: Vince Caruso, CEO and C0 Founder of New to The Street, commented: 'We're excited to bring audiences Show Number 675, showcasing disruptive companies across multiple sectors. As we expand our platform on Bloomberg, Fox Business, and digital syndication, we remain committed to helping innovators scale their story and visibility.' Show Number 675 will also stream on the New to The Street YouTube channel (2.9M+ subscribers), and be shared across social media and digital distribution networks globally. For media, sponsorship, or interview inquiries related to Show Number 675: Monica Brennan [email protected] About New to The Street Since 2009, New to The Street has produced over 675 episodes, airing weekly on Bloomberg Television and Fox Business as sponsored programming. Known for combining linear TV with digital media, social amplification, and billboard coverage, New to The Street provides a powerful media platform for public and private companies looking to elevate their visibility. SOURCE: New To The Street press release
Yahoo
18-06-2025
- Business
- Yahoo
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds
STATEN ISLAND, N.Y., June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a warrant inducement agreement (the "Letter Agreement") with a certain holder ("Holder") of existing warrants to purchase up to an aggregate of 4,445,435 shares of common stock (the "Existing Warrants") having exercise prices ranging from $3.25 to $3.26 per share, issued by the Company in July 2022 and May 2023, wherein the Holder agreed to exercise the Existing Warrants at a reduced exercise price of $0.675 per share, resulting in gross proceeds of approximately $2.67 million, before deducting offering fees and other expenses payable by the Company. In consideration for the exercise of the Existing Warrants for cash, the investors received 6,223,609 G-1 warrants (the "G-1 Warrants") and 2,667,261 G-2 warrants (the "G-2 Warrants) to purchase up to an aggregate of 8,890,870 shares of common stock (the "New Warrants"). The G-1 Warrants are exercisable immediately at an exercise price of $0.425 per common share and will expire five years from the issuance date. The G-2 Warrants are exercisable upon shareholder approval at an exercise price of $0.425 per common share and will expire five years from the issuance date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective resale registration statements on Form S-1 (File Nos. 333-267412 and 333-273015). The transaction is expected to close no later than June 20, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the exercise for working capital and general corporate purposes. The New Warrants are being issued in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such New Warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the New Warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Ibezapolstat Ibezapolstat is the Company's lead antibiotic candidate advancing to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillinresistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, the timing and completion of the offering; the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law. Investor Contact: Acurx Pharmaceuticals, Inc. David P. Luci, President & Chief Executive Officer Tel: 917-533-1469 Email: davidluci@ View original content: SOURCE Acurx Pharmaceuticals, Inc. Sign in to access your portfolio
Miami Herald
09-06-2025
- Business
- Miami Herald
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
PetVivo and Acurx Pharmaceuticals Exceed 200,000 Views as investor Demand for Long-Form Corporate Storytelling Surges NEW YORK CITY, NEW YORK / ACCESS Newswire / June 9, 2025 / New to The Street, the nation's leading financial media brand for long-form investor communications, proudly announces record-breaking viewership across its newest documentary-style programs. Its latest feature on IMG Academy surpassed 126,000 views in only 12 days on YouTube, marking a new milestone for the brand's flagship long-form format. Meanwhile, features on PetVivo Holdings, Inc. (NASDAQ:PETV) and Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) have crossed 200,000 views, reinforcing New to The Street's position as a go-to media platform for delivering cinematic, investor-focused storytelling at scale. Watch the full specials here: IMG Academy: PetVivo: Acurx Pharmaceuticals: Since 2009, New to The Street has produced thousands of 7-10-minute segments featuring public company CEOs and C-suite leaders, broadcast as sponsored programming on Bloomberg Television and FOX Business. The addition of 27-28-minute documentary specials represents a strategic evolution in media format-now delivering immersive brand narratives that are licensed, broadcast, and featured across a YouTube network with more than 2.5 million subscribers. Following national TV exposure, these pieces are supported by earned media syndication, social media campaigns, and Times Square billboard placements-providing a 360° distribution model for maximum investor engagement. For media, sponsorship, or booking inquiries, contact:Monica BrennanMonica@ About New to The Street:New to The Street is a nationally syndicated financial media platform delivering long-form television interviews, corporate documentaries, and multi-channel distribution across Bloomberg TV, FOX Business, as sponsored programming and one of the largest business YouTube channels in the industry. With over 245 million weekly household reach and 2.54M+ subscribers, the brand is redefining how business stories are told-and seen. SOURCE: New To The Street
Associated Press
09-06-2025
- Business
- Associated Press
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days
PetVivo and Acurx Pharmaceuticals Exceed 200,000 Views as investor Demand for Long-Form Corporate Storytelling Surges NEW YORK CITY, NEW YORK / ACCESS Newswire / June 9, 2025 / New to The Street, the nation's leading financial media brand for long-form investor communications, proudly announces record-breaking viewership across its newest documentary-style programs. Its latest feature on IMG Academy surpassed 126,000 views in only 12 days on YouTube, marking a new milestone for the brand's flagship long-form format. Meanwhile, features on PetVivo Holdings, Inc. (NASDAQ:PETV) and Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) have crossed 200,000 views, reinforcing New to The Street's position as a go-to media platform for delivering cinematic, investor-focused storytelling at scale. Watch the full specials here: 'These are not typical interviews-they're broadcast-quality mini-documentaries that resonate across investor and consumer audiences alike,' said Vince Caruso, Co-Founder and CEO of New to The Street. 'We're combining Wall Street-level insight with storytelling that connects emotionally and visually. Companies are seeing it translate directly into visibility and traction.' Since 2009, New to The Street has produced thousands of 7-10-minute segments featuring public company CEOs and C-suite leaders, broadcast as sponsored programming on Bloomberg Television and FOX Business. The addition of 27-28-minute documentary specials represents a strategic evolution in media format-now delivering immersive brand narratives that are licensed, broadcast, and featured across a YouTube network with more than 2.5 million subscribers. Following national TV exposure, these pieces are supported by earned media syndication, social media campaigns, and Times Square billboard placements-providing a 360° distribution model for maximum investor engagement. 'The data is crystal clear-audiences are spending more time with high-quality, long-form content,' added Caruso. 'This format allows companies to fully control their narrative, showcase innovation, and build trust-all while generating viewership numbers that rival traditional media.' For media, sponsorship, or booking inquiries, contact: Monica Brennan [email protected] About New to The Street: New to The Street is a nationally syndicated financial media platform delivering long-form television interviews, corporate documentaries, and multi-channel distribution across Bloomberg TV, FOX Business, as sponsored programming and one of the largest business YouTube channels in the industry. With over 245 million weekly household reach and 2.54M+ subscribers, the brand is redefining how business stories are told-and seen. SOURCE: New To The Street press release
